Enzo Biochem, Inc. (NYSE:ENZ) Director Gregory M. Bortz sold 42,005 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $9.82, for a total value of $412,489.10. Following the sale, the director now directly owns 292,875 shares of the company’s stock, valued at $2,876,032.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Enzo Biochem, Inc. (ENZ) opened at $9.99 on Friday.

WARNING: “Gregory M. Bortz Sells 42,005 Shares of Enzo Biochem, Inc. (ENZ) Stock” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.watchlistnews.com/gregory-m-bortz-sells-42005-shares-of-enzo-biochem-inc-enz-stock/1677895.html.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Marshall Wace North America L.P. increased its position in Enzo Biochem by 159.5% during the 2nd quarter. Marshall Wace North America L.P. now owns 76,375 shares of the medical research company’s stock worth $840,000 after purchasing an additional 46,943 shares during the period. Bank of New York Mellon Corp increased its position in Enzo Biochem by 7.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 221,166 shares of the medical research company’s stock worth $2,442,000 after purchasing an additional 14,719 shares during the period. Teachers Advisors LLC increased its position in Enzo Biochem by 25.6% during the 1st quarter. Teachers Advisors LLC now owns 140,745 shares of the medical research company’s stock worth $1,178,000 after purchasing an additional 28,722 shares during the period. Vanguard Group Inc. increased its position in Enzo Biochem by 9.2% during the 1st quarter. Vanguard Group Inc. now owns 1,665,758 shares of the medical research company’s stock worth $13,943,000 after purchasing an additional 139,901 shares during the period. Finally, Prudential Financial Inc. acquired a new position in Enzo Biochem during the 1st quarter worth approximately $149,000. Institutional investors own 62.07% of the company’s stock.

Several research firms have commented on ENZ. BidaskClub raised Enzo Biochem from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Zacks Investment Research downgraded Enzo Biochem from a “buy” rating to a “hold” rating in a research note on Tuesday, August 15th. Finally, TheStreet downgraded Enzo Biochem from a “b” rating to a “c+” rating in a research note on Wednesday, September 27th.

Enzo Biochem Company Profile

Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.

Receive News & Ratings for Enzo Biochem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.